Literature DB >> 492618

High-risk prematurity--progestin treatment and steroid studies.

J W Johnson, P A Lee, A S Zachary, S Calhoun, C J Migeon.   

Abstract

Studies have been undertaken regarding the efficacy and modus operandi of 17 alpha-hydroxyprogesterone caproate (17 alpha-OHP-C) in preventing premature labor in high-risk patients. In a total of 70 patients, the treated patient population had a prematurity rate (12.8%) and a perinatal mortality rate (5%) which were significantly lower than those of the total placebo or untreated patient group (40.9 and 25%, respectively). In addition, sequential plasma steroid values were determined in 21 patients, 10 of whom delivered prematurely. The results indicate that low plasma progesterone (P) and 17 alpha-hydroxyprogesterone (17 alpha-OHP) levels precede the onset of preterm labor by weeks. Successful treatment with 17 alpha-OHP-C was characterized by elevated P levels. Plasma estradiol (E2) and cortisol (C) values did not vary with time of delivery or treatment. These findings support the progesterone block theory as an important mechanism affecting preterm delivery in this high-risk population.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 492618

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  8 in total

Review 1.  Progesterone treatment to prevent preterm birth.

Authors:  Paul J Meis; Alicia Aleman
Journal:  Drugs       Date:  2004       Impact factor: 9.546

2.  Comparison of progesterone and glucocorticoid receptor binding and stimulation of gene expression by progesterone, 17-alpha hydroxyprogesterone caproate, and related progestins.

Authors:  Barbara J Attardi; Anthony Zeleznik; Hyagriv Simhan; Jye Ping Chiao; Donald R Mattison; Steve N Caritis
Journal:  Am J Obstet Gynecol       Date:  2007-12       Impact factor: 8.661

Review 3.  Recurrent preterm birth.

Authors:  Shali Mazaki-Tovi; Roberto Romero; Juan Pedro Kusanovic; Offer Erez; Beth L Pineles; Francesca Gotsch; Pooja Mittal; Nandor Gabor Than; Jimmy Espinoza; Sonia S Hassan
Journal:  Semin Perinatol       Date:  2007-06       Impact factor: 3.300

Review 4.  17 α-Hydroxyprogesterone caproate (Makena™): in the prevention of preterm birth.

Authors:  Emma D Deeks
Journal:  Paediatr Drugs       Date:  2011-10-01       Impact factor: 3.022

Review 5.  Progestin treatment for the prevention of preterm birth.

Authors:  Miha Lucovnik; Ruben J Kuon; Linda R Chambliss; William L Maner; Shao-Qing Shi; Leili Shi; James Balducci; Robert E Garfield
Journal:  Acta Obstet Gynecol Scand       Date:  2011-06-27       Impact factor: 3.636

6.  Salivary progesterone and estriol among pregnant women treated with 17-alpha-hydroxyprogesterone caproate or placebo.

Authors:  Mark A Klebanoff; Paul J Meis; Mitchell P Dombrowski; Yuan Zhao; Atef H Moawad; Allison Northen; Baha M Sibai; Jay D Iams; Michael W Varner; Steve N Caritis; Mary J O'Sullivan; Kenneth J Leveno; Menachem Miodovnik; Deborah Conway; Ronald J Wapner; Marshall Carpenter; Brian M Mercer; Susan M Ramin; John M Thorp; Alan M Peaceman
Journal:  Am J Obstet Gynecol       Date:  2008-05-23       Impact factor: 8.661

7.  Relationship between 17-hydroxyprogesterone caproate concentrations and gestational age at delivery in twin gestation.

Authors:  Steve N Caritis; Hyagriv N Simhan; Yuan Zhao; Dwight J Rouse; Alan M Peaceman; Anthony Sciscione; Catherine Y Spong; Michael W Varner; Fergal D Malone; Jay D Iams; Brian M Mercer; John M Thorp; Yoram Sorokin; Marshall Carpenter; Julie Lo; Susan M Ramin; Margaret Harper
Journal:  Am J Obstet Gynecol       Date:  2012-08-06       Impact factor: 8.661

8.  Pharmacokinetics of Hydroxyprogesterone Caproate and its Primary Metabolites during Pregnancy.

Authors:  Kim A Boggess; Jeffrey B Baker; Amy P Murtha; Alan M Peaceman; Dinesh M Shah; Sylvia L Siegfried; Robert Birch
Journal:  AJP Rep       Date:  2018-05-14
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.